Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE4B | Q07343 | 9/20 | 0.80 |
| ▸ | PDE4D | Q08499 | 4/20 | 0.48 |
| ▸ | POLB | P06746 | 2/20 | 0.47 |
| ▸ | MEN1 | O00255 | 1/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.47 |
| ▸ | PDE4A | P27815 | 1/20 | 0.44 |
| ▸ | PDE4C | Q08493 | 1/20 | 0.44 |
| ▸ | PARP1 | P09874 | 1/20 | 0.40 |
| ▸ | ACHE | P22303 | 1/20 | 0.39 |
| ▸ | BACE1 | P56817 | 1/20 | 0.39 |
| ▸ | HTR1A | P08908 | 1/20 | 0.38 |
| ▸ | ADRA1D | P25100 | 1/20 | 0.38 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.38 |
| ▸ | ADRA1B | P35368 | 1/20 | 0.38 |
| ▸ | GHSR | Q92847 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4707865 | 0.89 | PDE4B (0.62) | PDE4BPDE4DPOLBPDE4APDE4C | |
| SCHEMBL4708354 | 0.89 | PDE4B (1.00) | PDE4BPDE4DMEN1KMT2APDE4A | |
| SCHEMBL4709069 | 0.89 | PDE4B (0.62) | PDE4BPDE4DPDE4APDE4CPARP1 | |
| SCHEMBL4058811 | 0.86 | PDE4B (0.70) | PDE4BPDE4DPOLBPDE4APDE4C | |
| SCHEMBL4707247 | 0.85 | PDE4B (0.75) | PDE4BPDE4DMEN1KMT2APDE4A | |
| SCHEMBL4708948 | 0.85 | PDE4B (0.58) | PDE4BPDE4DPOLBPDE4APDE4C | |
| SCHEMBL4708776 | 0.85 | PDE4B (0.80) | PDE4BACHEBACE1HTR1AADRA1D | |
| SCHEMBL4709794 | 0.85 | PDE4B (0.57) | PDE4BPDE4DPOLBMEN1KMT2A | |
| SCHEMBL3036290 | 0.84 | PDE4B (0.56) | PDE4BPDE4DPOLBMEN1KMT2A | |
| SCHEMBL4708322 | 0.84 | PDE4B (0.90) | PDE4BHTR1AADRA1DADRA1AADRA1B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7459453-B2 | Pyridazin-3(2H)-one derivatives as PDE4 inhibitors | LABORATORIOS ALMIRALL, S.A. (ES) | 2008-12-02 | — | — | US | claimed |
| US-20060052379-A1 | Pyridazin-3(2h)-one derivatives as pde4 inhibitors | LABORATORIOS ALMIRALL, S.A. (ES) | 2006-03-09 | — | — | US | claimed |
| US-7459453-B2 | Pyridazin-3(2H)-one derivatives as PDE4 inhibitors | LABORATORIOS ALMIRALL, S.A. (ES) | 2008-12-02 | — | — | US | disclosed |
| US-20080269235-A1 | PYRIDAZIN-3 (2H) -ONE DERIVATIVES AS PDE4 INHIBITORS | DAL PIAZ VITTORIO | 2008-10-30 | — | — | US | disclosed |
| US-20060052379-A1 | Pyridazin-3(2h)-one derivatives as pde4 inhibitors | LABORATORIOS ALMIRALL, S.A. (ES) | 2006-03-09 | — | — | US | disclosed |
| EP-1503992-A1 | PYRIDAZIN-3(2H)-ONE DERIVATIVES AS PDE4 INHIBITORS | Almirall Prodesfarma, S.A. (ES) | 2005-02-09 | — | — | EP | disclosed |
| WO-2003097613-A1 | PYRIDAZIN-3(2H)-ONE DERIVATIVES AS PDE4 INHIBITORS | ALMIRALL PRODESFARMA SA (ES) | 2003-11-27 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080269235-A1 | PYRIDAZIN-3 (2H) -ONE DERIVATIVES AS PDE4 INHIBITORS | PDE4A, PDE3A, PDE4B | PDE4B 3/4885PDE4D 9/4885POLB 1032/4885 |
| US-20060052379-A1 | Pyridazin-3(2h)-one derivatives as pde4 inhibitors | PDE4A, PDE3A, PDE4B | PDE4B 3/4885PDE4D 9/4885POLB 1032/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.